Posted by on June 15, 2020 3:23 pm
Categories: Baidu

Canaccord Genuity maintain the CRISPR Therapeutics with a Buy rating

[unable to retrieve full-text content]

Flush financial
2 hours ago

Flush Stock News 6 May 15, Canaccord Genuity maintain theCRISPR Therapeutics with a Buy rating,the latest target price of 84. 00 USD. Source: flush Financial Research Center authors latest articles added to promote investment stable domestic demand in the second quarter…

Baidu snapshot

Published at Mon, 15 Jun 2020 19:22:34 +0000